Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 8/2011

01-08-2011 | Original Article

Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607

Authors: Luigi Aloj, Michela Aurilio, Valentina Rinaldi, Laura D’ambrosio, Diego Tesauro, Petra Kolenc Peitl, Theodosia Maina, Rosalba Mansi, Elisabeth von Guggenberg, Lieke Joosten, Jane K. Sosabowski, Wouter A. P. Breeman, Erik De Blois, Stuart Koelewijn, Marleen Melis, Beatrice Waser, Karin Beetschen, Jean Claude Reubi, Marion de Jong

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2011

Login to get access

Abstract

Purpose

Specific overexpression of cholecystokinin 2 (CCK2)/gastrin receptors has been demonstrated in several tumours of neuroendocrine origin. In some of these cancer types, such as medullary thyroid cancer (MTC), a sensitive diagnostic modality is still unavailable and therapeutic options for inoperable lesions are needed. Peptide receptor radionuclide therapy (PRRT) may be a viable therapeutic strategy in the management of these patients. Several CCK2R-targeted radiopharmaceuticals have been described in recent years. As part of the European Union COST Action BM0607 we studied the in vitro and in vivo characteristics of 12 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-conjugated CCK2R binding peptides. In the present study, we analysed binding and internalization characteristics. Stability, biodistribution and imaging studies have been performed in parallel by other centres involved in the project.

Methods

Determination of IC50 values was performed using autoradiography, with DOTA-peptides displacing 125I-CCK from receptors on tissue sections from human tumours. Saturation binding and internalization experiments were performed using 111In-labelled peptides. The rat AR42J cell line and the human A431-CCK2R transfected cell line were utilized for in vitro experiments; dissociation constants (Kd) and apparent number of binding sites (Bmax) were determined. Internalization was determined in receptor-expressing cells by incubating with tracer amounts of peptide at 37 and 4°C for different times up to 120 min. Surface-bound peptide was then stripped either by acid wash or subsequent incubation with 1 μM unlabelled peptide at 4°C.

Results

All peptides showed high receptor affinity with IC50 values ranging from 0.2 to 3.4 nM. Saturation experiments also showed high affinity with Kd values in the 10−9–10−8 M range. Bmax values estimated in A431-CCK2R cells ranged from 0.6 to 2.2 × 106 per cell. All peptides showed high levels of internalization when incubated at 37°C.

Conclusion

All DOTA-conjugated peptides showed high receptor binding and internalization properties and appear suitable for further characterization, as described in other articles of this issue.
Literature
1.
go back to reference Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRef Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389–427.PubMedCrossRef
2.
go back to reference Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377–86.PubMed Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res 1997;57:1377–86.PubMed
3.
go back to reference Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol 2009;21:5–10.PubMedCrossRef Roman S, Mehta P, Sosa JA. Medullary thyroid cancer: early detection and novel treatments. Curr Opin Oncol 2009;21:5–10.PubMedCrossRef
4.
go back to reference Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140–6.PubMedCrossRef Béhé M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging 2003;30:1140–6.PubMedCrossRef
5.
go back to reference Behr TM, Béhé M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999;43:268–80.PubMed Behr TM, Béhé M, Becker W. Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 1999;43:268–80.PubMed
6.
go back to reference Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 2008;35:1868–77. doi:10.1007/s00259-008-0803-4.PubMedCrossRef Good S, Walter MA, Waser B, Wang X, Müller-Brand J, Béhé MP, et al. Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. Eur J Nucl Med Mol Imaging 2008;35:1868–77. doi:10.​1007/​s00259-008-0803-4.PubMedCrossRef
7.
go back to reference Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, et al. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004;45:485–94.PubMed Aloj L, Caracò C, Panico M, Zannetti A, Del Vecchio S, Tesauro D, et al. In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. J Nucl Med 2004;45:485–94.PubMed
8.
go back to reference Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481–90.PubMedCrossRef Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A, et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481–90.PubMedCrossRef
9.
go back to reference von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather SJ, et al. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem 2009;52:4786–93. doi:10.1021/jm900400w.CrossRef von Guggenberg E, Sallegger W, Helbok A, Ocak M, King R, Mather SJ, et al. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. J Med Chem 2009;52:4786–93. doi:10.​1021/​jm900400w.CrossRef
10.
go back to reference Roosenburg S, Laverman P, Joosten L, Eek A, Oyen WJ, de Jong M, et al. Stabilized (111)In-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. Bioconjug Chem 2010;21:663–70. doi:10.1021/bc900465y.PubMedCrossRef Roosenburg S, Laverman P, Joosten L, Eek A, Oyen WJ, de Jong M, et al. Stabilized (111)In-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. Bioconjug Chem 2010;21:663–70. doi:10.​1021/​bc900465y.PubMedCrossRef
11.
go back to reference Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007;48:615–22.PubMedCrossRef Mather SJ, McKenzie AJ, Sosabowski JK, Morris TM, Ellison D, Watson SA. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 2007;48:615–22.PubMedCrossRef
13.
go back to reference Nock BA, Maina T, Béhé M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 2005;46:1727–36.PubMed Nock BA, Maina T, Béhé M, Nikolopoulou A, Gotthardt M, Schmitt JS, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. J Nucl Med 2005;46:1727–36.PubMed
14.
go back to reference Fröberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:1265–72. doi:10.1007/s00259-009-1098-9.PubMedCrossRef Fröberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009;36:1265–72. doi:10.​1007/​s00259-009-1098-9.PubMedCrossRef
15.
go back to reference Béhé M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002;66:399–418. doi:10.1002/bip.10356.PubMedCrossRef Béhé M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 2002;66:399–418. doi:10.​1002/​bip.​10356.PubMedCrossRef
16.
go back to reference Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012–5.PubMed Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012–5.PubMed
17.
go back to reference Laverman P, Roosenburg S, Gotthardt M, Park J, Oyen WJ, de Jong M, et al. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging 2008;35:386–92. doi:10.1007/s00259-007-0604-1.PubMedCrossRef Laverman P, Roosenburg S, Gotthardt M, Park J, Oyen WJ, de Jong M, et al. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging 2008;35:386–92. doi:10.​1007/​s00259-007-0604-1.PubMedCrossRef
18.
go back to reference von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1209–18. doi:10.1007/s00259-006-0348-3.CrossRef von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1209–18. doi:10.​1007/​s00259-006-0348-3.CrossRef
19.
go back to reference Ocak M, Helbok A, Rangger C, Peitl PK, Nock B, Morelli G, et al. Comparison of biological stability and metabolism of CCK2-receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging 2011, in press. Ocak M, Helbok A, Rangger C, Peitl PK, Nock B, Morelli G, et al. Comparison of biological stability and metabolism of CCK2-receptor targeting peptides, a collaborative project under COST BM0607. Eur J Nucl Med Mol Imaging 2011, in press.
20.
go back to reference Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T, et al. Comparative biodistribution of twelve gastrin/CCK2 receptor targeting peptides. Eur J Nucl Med Mol Imaging 2011, in press. Laverman P, Joosten L, Eek A, Roosenburg S, Peitl PK, Maina T, et al. Comparative biodistribution of twelve gastrin/CCK2 receptor targeting peptides. Eur J Nucl Med Mol Imaging 2011, in press.
21.
go back to reference Sosabowski JK, Finucane C, Foster JM, Ellison D, Burnet J, Laverman P, et al. Comparison of 111In-labelled CCK2-receptor targeting peptides using NanoSPECT/CT imaging. Submitted for publication 2011. Sosabowski JK, Finucane C, Foster JM, Ellison D, Burnet J, Laverman P, et al. Comparison of 111In-labelled CCK2-receptor targeting peptides using NanoSPECT/CT imaging. Submitted for publication 2011.
22.
go back to reference Giragossian C, Mierke DF. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin-2 receptor. Biochemistry 2002;41:4560–6.PubMedCrossRef Giragossian C, Mierke DF. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin-2 receptor. Biochemistry 2002;41:4560–6.PubMedCrossRef
23.
go back to reference Roosenburg S, Laverman P, van Delft FL, Boerman OC. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 2010. doi:10.1007/s00726-010-0501-y. Roosenburg S, Laverman P, van Delft FL, Boerman OC. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 2010. doi:10.​1007/​s00726-010-0501-y.
24.
go back to reference D’Andrea LD, Testa I, Panico M, Di Stasi R, Caracò C, Tarallo L, et al. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl. Biopolymers 2008;90:707–12. doi:10.1002/bip.21041.PubMedCrossRef D’Andrea LD, Testa I, Panico M, Di Stasi R, Caracò C, Tarallo L, et al. In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with 99mTc-tricarbonyl. Biopolymers 2008;90:707–12. doi:10.​1002/​bip.​21041.PubMedCrossRef
25.
go back to reference Tornesello AL, Aurilio M, Accardo A, Tarallo L, Barbieri A, Arra C, et al. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison. J Pept Sci 2011;17:405–12. doi:10.1002/psc.1327.PubMedCrossRef Tornesello AL, Aurilio M, Accardo A, Tarallo L, Barbieri A, Arra C, et al. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison. J Pept Sci 2011;17:405–12. doi:10.​1002/​psc.​1327.PubMedCrossRef
26.
go back to reference Marsouvanidis PJ, Tatsi A, Nock BA, Krenning EP, Maina T, de Jong M. [111In]Sargastrin, a Gastrin I-based radioligand targeting CCK2-R-positive tumors in vivo. Eur J Nucl Med Mol Imaging 2009;36:S259. Marsouvanidis PJ, Tatsi A, Nock BA, Krenning EP, Maina T, de Jong M. [111In]Sargastrin, a Gastrin I-based radioligand targeting CCK2-R-positive tumors in vivo. Eur J Nucl Med Mol Imaging 2009;36:S259.
27.
go back to reference Kolenc-Peitl P, Mansi R, Tamma ML, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem. In press 2011. Kolenc-Peitl P, Mansi R, Tamma ML, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, et al. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem. In press 2011.
Metadata
Title
Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607
Authors
Luigi Aloj
Michela Aurilio
Valentina Rinaldi
Laura D’ambrosio
Diego Tesauro
Petra Kolenc Peitl
Theodosia Maina
Rosalba Mansi
Elisabeth von Guggenberg
Lieke Joosten
Jane K. Sosabowski
Wouter A. P. Breeman
Erik De Blois
Stuart Koelewijn
Marleen Melis
Beatrice Waser
Karin Beetschen
Jean Claude Reubi
Marion de Jong
Publication date
01-08-2011
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-011-1816-y

Other articles of this Issue 8/2011

European Journal of Nuclear Medicine and Molecular Imaging 8/2011 Go to the issue